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Background: Asthma is an inflammatory disease of the airways, but in clinical practice inflammation is rarely
monitored. The aim of this study was to assess the level of airway inflammation in steroid naïve adult and pediatric
patients with intermittent asthma over one year.
Methods: 54 children and 50 adults with intermittent asthma (GINA step 1) were included. On up to 6 visits lung
function, airway hyperresponsiveness to methacholine (PC20FEV1), sputum eosinophils and exhaled nitric oxide
(FeNO) were assessed.
Results: 36 pediatric and 34 adult patients were able to produce at least three adequate sputum samples over the
study period and were included into the analysis.
In 8 children (22%) the percentage of sputum eosinophils was always below 2.5%. A higher level of eosinophils
(>2.5%) was found on at least one visit in 16 (44%) and always >2.5% in 12 children (33%). In the adult group the
respective numbers were 14 patients (41%) with always low (<2.5%), 17 (50%) with at least once over 2.5% and
three patients (9%) were always above the threshold of 2.5% sputum eosinophils.
Conclusion: These results demonstrate that a substantial number of children and adults with intermittent asthma
under ß-agonist treatment only, have variable or persistently high levels of eosinophilic airway inflammation.
Long-term studies are needed to observe the progression of asthma severity in such patient populations.
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Induced sputumBackground
Asthma is a chronic inflammatory disease of the air-
ways. The mildest form of the disease, intermittent
asthma is characterized by an almost normal lung func-
tion (FEV1 > 80% pred.), the use of a β-agonist less than
once a week (reliever medication) and nighttime symp-
toms less than twice per month. Peak-flow measure-
ments are generally normal, except in intermittent
periods of symptom worsening [1].* Correspondence: magnussen@pulmoresearch.de
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unless otherwise stated.It is known from cross sectional studies that patients
with intermittent asthma can have raised numbers of
sputum eosinophils [2,3]. However, no longitudinal stud-
ies are available showing the level of airway inflamma-
tion in these patients over longer periods of time. This
data is available for children with mild to moderate and
severe asthma only [4]. It has been shown that reducing
inflammation can lead to a lower level of basement
membrane thickening [5]. It is also known that a treat-
ment regimen aiming to keep sputum eosinophils below
3% reduces the asthma exacerbations [6-8]. In children
with asthma this strategy was not as successful [9].
It was the aim of this study to assess the level of air-
way inflammation in adult and pediatric patients with
intermittent asthma over one year. Over this period theal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of airway inflammation as well as PC20FEV1 and lung
function were measured. The patients were under stan-
dard supervision of their pneumologist, who treated
them based on lung function and symptoms according
to GINA guidelines [1]. The pneumologists were blinded
to the results of inflammatory parameters obtained in
the study centers. So there was no adjustment of treat-
ment based on inflammatory parameters.
Methods
Patients
The study was conducted in five German study sites. Fifty
adult patients were recruited in Leipzig, Grosshansdorf
and Wiesbaden, and 54 pediatric patients in Wesel and
Frankfurt. All patients had received a diagnosis of inter-
mittent asthma within 6 months prior to the study (GINA
step 1: according to asthma severity GINA 2002; cor-
responding to controlled asthma, treatment step 1
GINA 2013 [1]). The inclusion criteria were use of
beta-agonist <1/week (max. 4 puffs/occasion), nighttime
symptoms ≤ 2/month, no exacerbation 4 weeks prior
to a visit. The exclusion criteria were mild persistent
asthma (GINA step 2), a smoking history of more than
10 pack years, other severe comorbidities, pregnancy.
The study was approved by the Ethics Committee of
Medical Association Schleswig-Holstein, Bad Segeberg,
Germany. All adult patients and the parents of the
pediatric patients gave their written informed consent.
Medication
All patients received salbutamol at the beginning of the
study to be used as reliever medication. Subjects were
allowed to use cromoglycic acid, antihistamines or topical
corticosteroid medication for the treatment of nasal or eye
allergic symptoms during allergy season. Antihistamines,
if periodically needed, had to be stopped 48 hours
and corticosteroid preparations 2 weeks prior to a visit.
Patients were also allowed to use inhaled corticosteroidsFigure 1 Study design.periodically up to 2 weeks before a visit or cromoglycic
acid up to 1 week before a visit to relieve seasonal allergic
symptoms. Short acting beta-agonists and anticholinergics
were not allowed 6 hours, long acting beta-agonist or
anti-cholinergics were not allowed 24 hours or 15 days
prior to a visit. Oral antihistamines had to be stopped
48 hours prior to a visit. Oral steroids were not allowed
throughout the study.
Study design
The study comprised 7 visits over one year (Figure 1). In
the pre-study visit (screening), the medical history was
assessed and a physical examination, a skin prick test,
and a lung function test was performed. A blood sample
was taken for clinical chemistry, serum IgE and diffe-
rential blood cell count on visit 1. On all remaining visits
a spirometry, a methacholine challenge, analysis of
induced sputum (not visit 1) and a measurement of
FeNO were performed.
FeNO
The level of fractional exhaled NO was detected using a
NIOX NO-analyzer (Aerocrine AB, Solna, Sweden).
Measurements were performed according to the latest
ATS guidelines [10] and all NO-analyzers were calibrated
according to the manufacturer’s recommendations.
Spirometry
Lung function was measured according to the latest
ATS guidelines [11] using electronic spirometers (Viasys
Healthcare, Höchberg, Germany).
Sputum induction and analysis
Sputum induction was performed as previously described
[12]. Briefly, patients inhaled 3 and 4% nebulized saline
solution for two consecutive periods of 5 min each after
pretreatment with 200 μg salbutamol. Sputum plugs were
selected and pooled from all expectorated material. The
sputum processing was performed with Dithiothreitol
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Grosshansdorf by counting 400 non-squamous cells on
Giemsa-stained slides. Results were expressed as percen-
tage of non-squamous cells. The normal value of sputum
eosinophils was set to 2.5% according to Spanevello [14].
Methacholine challenge
Airway hyperresponsiveness was assessed by provocation
with nebulized methacholine in increasing concentra-
tions until a 20% fall in FEV1 (PC20FEV1) could be
detected [15].
Statistics
For data with normal distribution mean values and stan-
dard deviations, for all other parameters either geometric
mean values or medians were calculated. Compari-
sons between groups were performed by the Wilcoxon
Matched Pairs test. The Spearmen correlation coefficient
was calculated for the individual comparisons between




Patient characteristics are given in Table 1. Out of 104
patients 70 patients (36 pediatric/34 adults) were able to
produce three adequate sputum samples over the study
period. These patients were included into the data
analysis. Additional file 1: Table S1 provides details on
the allergy prevalences and Additional file 1: Table S2 on
medications and treatments.
Sputum eosinophils
We classified both pediatric and adult patients into three
groups (“always low”, “variable”, and “always high”)
based on the longitudinal sputum eosinophil percentages
using a cut-off value of 2.5%. Eight pediatric (22%) andTable 1 Patient characteristics
Pediatric patients Adult patients
n 54 36* 50 34*
gender (m/f) 30/24 21/15 29/21 21/13
age (years) 9.5 ± 2.0 9.9 ± 1.8 34.2 ± 10.4 34,4 ± 9.8
FeNO (ppb) 18.5 (26.1) 19.0 (37.3) 37.1 (69.1) 36.2 (63.3)
FEV1 (% pred.) 100.5 ± 12.8 100.7 ± 10.1 99.8 ± 11.7 103.1 (10.4)
PC20FEV1 (mg/ml) 0.75 (2.4) 1.4 (3.8) 0.9 (2.6) 1.3 (3.8)
IgE (IU/L) 171.5 (342) 152 (332) 188 (320) 199 (285)
Blood Eos (%) 6 (5) 6 (5) 3 (3) 4 (3)
Data of the screening visit separately presented as mean ± SD or median.
(interquartile range; IQR) for all patients and patients (*) able to produce at
least on 3.
Visits an adequate sputum sample. m: male, f: female.14 adult patients (41%) showed a low (<2.5%) eosinophil
count in all visits. In 16 children (44%) and 17 adults
(50%) more than 2.5% eosinophils were found in at least
one visit over the study period. For 12 children (33%)
and 3 adults (9%) sputum eosinophils were > 2.5% in all
visits (Figure 2). The individual values for lung function
(FEV1) and for the levels of exhaled NO (FeNO) sepa-
rately for these groups over the study periods are shown
in Additional file 2: Figure S1 and Additional file 3:
Figure S2.
Comparisons between patient groups with low, variable
and high levels of sputum eosinophils
Additional file 1: Table S3 shows the differences of
inflammatory parameters and FEV1 between groups and
separately for all visits. In adult patients the high eosino-
phil group also showed significantly higher FeNO values
based on the comparison at the different time points. In
contrast, the FeNO levels in the pediatric patients did
not differ significantly between the three groups.
The FEV1 (% predicted) values were not significantly
different between groups however, both the children and
adults with persistently high eosinophils tended to have
the lowest values.
The PC20FEV1 was significantly lower in adult patients
with persistently high eosinophil levels compared to the
low eosinophil group, indicating that these adult patients
were more sensitive to unspecific airway provocation.
Interestingly, the pediatric group with persistently low
sputum eosinophils showed the highest level of airway
hyperresponsiveness.
Additional file 1: Table S3 also provides the median
percentages for sputum neutrophils for the different
groups for all visits. Only in very rare occasions the
percentage of neutrophils exceeded 50%, so that the
neutrophilic asthma phenotype did not play a role in this
study.
Additional file 1: Table S4 shows the day and night-
time symptoms, the use of rescue medication as well as
the peak-flow variability in the morning and in the
evening. The data is derived from the diaries of the pa-
tients and summarizes the first 7 days following each
visit, which were generally not confounded by missing
data. Symptoms and use of rescue medication were as
low as expected in patients with intermittent asthma,
but there was a trend to larger peak-flow variability
especially in the adult patients with persistently high
eosinophil counts. However, these were only three pa-
tients and therefore this result has to be interpreted with
care.
Table 2 shows that pediatric as well as adult patients
with persistently high eosinophils had significantly higher
blood eosinophils at baseline and in pediatric patients
there was a trend to higher IgE levels.
Figure 2 Percentage of sputum eosinophils over the study period V1 – V5 separately for pediatric and adult patients and for
individual patients with always low (A, D), variable (B, E) and persistently high (C, F) percentages of sputum eosinophils. The cut-off
value of 2.5% (shaded area) is displayed. Sputum eosinophils = 0% were set to 0.05 to allow a logarithmic scaling.
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The FeNO levels showed a good to excellent reproduci-
bility over the study period. Furthermore, the correlation
coefficients between visits (separate for pediatric and
adult patients) ranged from 0.6 to 0.9 and all com-
parisons were statistically significant (p < 0.001, example
in Additional file 4: Figure S3). A similar result was




Gender m/f 6/2 12/4 3/9
Age years 9,5 (8,0; 11,5) 9 (8,0; 11,0) 10,5 (10,0; 11
IgE IU/L 217 (12,0; 898,0) 125 (59,0; 250,0) 175 (88,0; 589
Allergy# n 2/4/1/1 4/8/2/2 4/6/2/0
BloodEosV1 % 4,5 (2,5; 5,0) 6 (4,5; 8,0) 9 (6,5; 10,5)
ANOVA: *p < 0.05, **p < 0.01.
#Seasonal/perennial/perennial with seasonal peaks/other or not defined.the individual visits. The correlation for PC20FEV1 was
slightly weaker, but significant for all comparisons. As
shown in Additional file 4: Figure S3, the reproducibility
of eosinophils was weak for about half of all subjects
indicating the variability of eosinophilc airway inflamma-
tion in these patients.
We also looked at the correlation between different in-
flammatory markers. Figure 3 provides the data for theh persistently low, variable and persistently high sputum
Adult patients
P Low Variable High P
7/7 11/6 3/0
,0) 31 (27,0; 44,0) 36 (26,0; 38,0) 41 (32,0; 55,0)
,0) 190 (161,0; 411,0) 222 (128,5; 406,5) 75 (64,0; 168,0)
4/3/6/1 5/2/9/1 0/0/2/1
* 3 (3,0; 4,0) 4 (2,0; 7,0) 8 (7,0; 13,0)** **
Figure 3 Correlation between the percentage of sputum eosinophils and the level of exhaled NO (FeNO) for visit 1, 3 and 5, separately
for pediatric and adult patients. Patients with always low (A, D), variable (B, E) and persistently high (C, F) percentages of sputum eosinophils.
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visit 1, visit 3 and visit 5. There was a slightly better
correlation in adult patients.Relationship between airway inflammation and symptoms
There were generally only few symptoms in both pe-
diatric and adult subjects (Additional file 1: Table S4).
Considering the diary data of the first week following
each visit we did not find any significant correlations
between symptoms and the different measures of airway
inflammation assessed in this study.Discussion
In this longitudinal study over one year we found in-
creased levels of sputum eosinophils on at least one oc-
casion in 77% of the pediatric and 59% of the adult
patients with intermittent asthma. The three groups with
persistently low, variable and persistently high levels of
eosinophils differed with respect to FeNO levels and
blood eosinophils.Asthma is defined as a chronic inflammatory airway
disease, which is associated with symptoms, airway
hyperresponsiveness, and variable limitations in lung
function [1]. The phenotypes of asthma are diverse and
can be defined by the composition of induced sputum
[16,17]. While neutrophilic asthma is generally more dif-
ficult to treat, eosinophilc asthma usually responds well
to the treatment with corticosteroids [18,19]. Therefore,
it seems to be rational to measure the extent and the
characteristics of airway inflammation in asthma both
for diagnostic reasons and to monitor the disease. This
is emphasized by studies that adapted the dose of
inhaled steroids to keep sputum eosinophils below the
normal cutoff-value of 3% and that were able to reduce
the exacerbations rate of adult asthmatic patients [6,7].
While there is one study showing that this strategy is
not as successful in children [9], there is also data from
the General Practice Research database in the UK show-
ing that increasing the anti-inflammatory treatment as a
step-up therapy in uncontrolled asthma is superior in
avoiding severe exacerbations and hospital admissions
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rithm for the treatment was presented [21]. However,
the diagnostic use of markers of airway inflammation
was not mentioned.
Our data demonstrates that in a large number of stable
asthmatic patients with nearly normal lung function and
with just reliever medication on demand, a significant
level of undiscovered eosinophilic airway inflammations
exists. For more severe asthma patients who had been
under ICS treatment at least periodically a phenotype
with persistent eosinophilic airway inflammation has
been described before [22]. Raised levels of airway in-
flammation were also reported by Fleming and co-
workers both in adults and pediatric patients with mild
to moderate asthma, of whom most (>90%) were under
steroid treatment [4]. In line with the largest part of the
patients investigated in our study, the inflammatory
phenotype was variable over time [4].
We measured lung function, sputum composition,
FeNO and airway hyperresponsiveness over a time
period of one year. The correlation between visits for
FeNO and PC20FEV1 was generally good and statisti-
cally significant. For sputum eosinophils this was not
true for a large number of patients reflecting the variable
sputum levels over time, which has been reported before
[4]. Sputum eosinophils and FeNO correlated in the
adult patients, which is in line with published data
[23,24]. A larger variability of FeNO values was observed
in the pediatric group, most likely due to the fact that
FeNO is influenced by body size [10,25], which is more
variable in children and juveniles (in this study from 7 to
14 years) than in adults.
Sputum eosinophils were negatively correlated to the
PC20FEV1 in the adult group, indicating, that in the
presence of more airway inflammation, there is generally
also a higher degree of unspecific airway hyperrespon-
siveness [26]. There is evidence that the association
between PC20FEV1 and eosinophilic airway inflammation
depends on the duration of the disease [27]. Groenke
and colleagues showed that the correlation with eosino-
phils disappeared with increasing asthma duration and
related more to the baseline FEV1, possibly reflecting
structural alterations in chronic asthma. Unexpectedly,
the pediatric group with persistently low eosinophil
counts always showed the highest level of hyper-
responsiveness. Neither differences in age or in gender
distribution (Table 2) can explain this observation.
Looking at seasonal and perennial sensitized pediatric
patients separately (Table 2) showed a comparable result.
Only in perennial sensitized children with additional sea-
sonal symptoms the degree of hyperresponsiveness was
similar in the high and low sputum eosinophil groups.
However, due to low number these subgroup result need
to be interpreted with care.Our study has some limitations: As often seen in large
longitudinal studies, the follow up of patients is sometimes
difficult. We also experienced a certain amount of non-
adherence to the study protocol resulting in missing values
due to missed visits. Another problem was the quality of
sputum samples, which was insufficient in a number of
cases. Therefore, the assignment to the groups with high
and low percentage of eosinophils could not be based on
the results of all visits, making also the use of more ad-
vanced statistical methods difficult. While all medications
were documented (Additional file 1: Table S2), we did not
explicitly define and record asthma exacerbations.
It has to be emphasized, that the chosen cutoff-value
of 2.5% does not discriminate between healthy and asth-
matic patients and that high eosinophil counts can also
occur in patients with rhinitis and mirrors airway in-
flammation during allergen exposure [28]. The compari-
son between groups with respect to the other markers of
inflammation was performed by comparing the results
of the individual visits. As the study outline indicates
these visits were not performed simultaneously, however,
close enough between different groups that such a com-
parison appeared to be justified.
For pediatric and adult patients with persistent airway
inflammation regular bronchodilator treatment through-
out most of the study period was sufficient to control
symptoms and airflow limitations. Therefore our data
raises the question for the need of anti-inflammatory
treatment in patients with intermittent asthma. The dis-
cussion, whether mild asthma patient should be treated
with steroids is old [29,30]. The results of peak-flow
measurements and the record of reliever medication in-
take collected in the diaries at visit 1 and visit 5 of our
study did not provide evidence for a worsening of symp-
toms in the high eosinophil group. There was also no
significant change in FEV1 and PC20FEV1 between visit
1 and 5. However, the already mentioned short term
treatment studies [5,6] would suggest that a risk for
more exacerbations and for remodeling within the
airways exists. There is also evidence for more airway
inflammation in steroid naïve asthma patients that
showed a fast decline in lung function over a 5 year
period [31]. Furthermore, it has been shown that redu-
cing airway inflammation can lead to an improvement of
symptoms [32]. In the Brussel declaration it is empha-
sized that the knowledge of ongoing inflammation in
mild asthma requires the need for short and efficient
anti-inflammatory treatment [33].
Conclusion
The results of our study suggest that including the regular
measurement of airway inflammation into the standard
monitoring of intermittent asthma patients (GINA step1)
can identify patients with variable or even persistent
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severe asthma are attributed to ongoing and potentially to
the long history of abnormal inflammatory processes, it
appears justified to argue that keeping inflammation as
low as possible has the potential for a more beneficial
outcome. However, long term prospective studies are
required, to resolve this issue.
Additional files
Additional file 1: Table S1. Allergy prevalences - skin prick testing.
Table S2. Medications: Number of patients with specific treatments.
Table S3. Comparison of inflammatory parameters and FEV1 between
pediatric and adult patients with persistently low, variable and persistently
high sputum eosinophils. Table S4. Comparison of symptoms between
pediatric and adult patients with persistently low, variable and persistently
high sputum eosinophils.
Additional file 2: Figure S1. Concentration of FeNO over the study
period V1 – V5 separately for pediatric and adult patients and for
individual patients with always low (A, D), variable (B, E) and persistently
high (C, F) percentages of sputum eosinophils.
Additional file 3: Figure S2. FEV1 (% pred.) over the study period
V1 – V5 separately for pediatric and adult patients and for individual
patients with always low (A, D), variable (B, E) and persistently high (C, F)
percentages of sputum eosinophils.
Additional file 4: Figure S3. Repeatability of FeNO (A), sputum
eosinophils (B) and PC20FEV1 (C) between visit 1a and visit 5. The line of
identity is presented in each graph. Circles represent pediatric, squares
represent adult patients.
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